KRAS mutation is the most common oncogenic aberration in NSCLC with up to 30% incidence in patients with adenocarcinoma in Western countries [76], and is associated with increased benefit from ICIs when it does not co-occur with STK11 or KEAP1 mutations. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.